Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Real Time Quote from BATS)

$6.74 USD

6.74
236,331

+0.02 (0.30%)

Updated Jul 22, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.

Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock

by Zacks Equity Research

Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View

by Zacks Equity Research

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.

Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of 300.00% and 36.62%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Amends Linzess Agreement with AstraZeneca in China

by Zacks Equity Research

Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.

Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

by Zacks Equity Research

Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.

Benjamin Rains headshot

Investors Can Find Big Returns with this First Profit Screen

by Benjamin Rains

We are taking a look at our 'First Profit' stock screen today. The idea is to search for companies that just reported their first quarterly profit within the last year because these firms could prove to be big winners for investors...

Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study

by Zacks Equity Research

Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.

Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of 214.29% and 12.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News For Jun 20, 2019

by Zacks Equity Research

Companies In The News Are: VIAB,CBS,ADBE,X,AGN,IRWD

Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients

by Zacks Equity Research

Ironwood (IRWD) and Allergan's Linzess meets the goal in a late-stage study for treating adult patients with IBS-C. Shares rise as the drug reduces bloating, pain and discomfort in IBS-C patients.

Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

by Zacks Equity Research

Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report?

by Zacks Equity Research

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall

by Zacks Equity Research

Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.

    Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Ironwood (IRWD) delivered earnings and revenue surprises of -62.50% and -17.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

    5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates

    by Zacks Equity Research

    So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.

    Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    by Zacks Equity Research

    Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Will Ironwood Suffer From Dependence on Linzess' Progress?

    by Zacks Equity Research

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.

    Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?

    by Zacks Equity Research

    Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise

    by Zacks Equity Research

    Ironwood (IRWD) beats on both earnings and sales in the fourth quarter. Shares up.

    Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Ironwood (IRWD) delivered earnings and revenue surprises of 88.24% and 50.70%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline

    by Zacks Equity Research

    Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.